Diosmin and Hesperidin for Circulation and Lymphatic Health

Published by Lymphatic Health Co., the company behind Lympha.

Diosmin and hesperidin have a substantial human research history in venous health. Studies of their best-known combined preparation have reported improvements in leg heaviness, swelling, and measured ankle size. Their relevance to lymphedema begins with the close relationship between venous function and lymphatic drainage. That clinical record and physiological connection are why this pair forms the venous foundation of Lympha, and why it is the starting point for our ingredient series.

What are diosmin and hesperidin

Diosmin and hesperidin belong to a family of compounds called flavonoids. Hesperidin occurs naturally in citrus fruits, particularly their peels. Diosmin is a closely related flavonoid that has been widely studied in venous health.

You will often see them discussed alongside the term micronized purified flavonoid fraction, or MPFF. This is a defined preparation used in much of the clinical research, including studies of the medicine Daflon. The classic MPFF composition is approximately 90% diosmin and 10% other flavonoids expressed as hesperidin. Read the description of the preparation in the human absorption study.

This defined combination is a major reason diosmin and hesperidin are so often discussed together. We selected both for Lympha because this established approach has a substantial clinical record in venous health.

What the human studies show

Much of the clinical research involves people with chronic venous disease, a group of conditions affecting blood return through the veins. This is a useful setting for studying heaviness and swelling because impaired venous function can increase pressure in the legs and contribute to fluid accumulation.

Less heaviness and swelling in placebo controlled trials

A 2018 systematic review and meta-analysis brought together seven randomized, double-blind, placebo-controlled trials involving 1,692 people with chronic venous disease. Compared with placebo, MPFF improved leg heaviness, pain, the feeling of swelling, cramps, and functional discomfort. The analysis also found a reduction in ankle circumference and an improvement in quality of life. Read the meta-analysis of placebo-controlled trials.

Those findings matter because they connect two things readers care about: how the legs feel and measurable changes in swelling. The placebo comparison also makes this an especially useful part of the evidence behind our ingredient selection.

Measured reductions in ankle and calf size

A 2023 review focused specifically on lower-leg swelling. It combined eight studies involving 1,635 people with chronic venous disease who received 1,000 mg of MPFF daily. After two months, ankle circumference had decreased by an average of approximately 6.0 mm from the starting measurement, while calf circumference had decreased by approximately 5.7 mm. Read the review of lower-limb edema.

These are changes from participants’ starting measurements, pooled across studies with different designs and varying results. They add objective measurements to the clinical picture of improved leg comfort.

A clinical record extending over months

The RELIEF study followed 5,052 people with symptomatic venous disease across 23 countries during six months of MPFF treatment. Researchers reported progressive improvements in symptoms, including leg heaviness and the sensation of swelling, together with improvements in quality of life. Read the RELIEF study.

As observational follow-up without a placebo comparison, RELIEF adds evidence about the experience of thousands of people over months, with symptoms and quality of life assessed throughout treatment.

Why venous research matters for lymphatic health

Your veins and lymphatic vessels share a role in returning fluid toward the heart. Veins carry blood back from the tissues. Lymphatic vessels collect fluid and proteins from the spaces around cells and return them to the bloodstream.

The connection starts before fluid enters a lymphatic vessel. Pressure within small blood vessels helps determine how much fluid filters into the surrounding tissue. When venous pressure remains elevated, it can encourage additional filtration, increasing the fluid load that the lymphatic system must handle. Read the review of microvascular fluid exchange.

This is why venous function belongs in a discussion of lymphatic health: it influences the amount of fluid the lymphatic system needs to collect and return. Our article Why Circulation Matters for Lymphatic Health explains these connections in more detail.

How diosmin and hesperidin relate to lymphedema

Lymphedema develops when lymphatic drainage cannot adequately clear fluid from the tissues. For someone managing that challenge, the amount of fluid entering those tissues becomes especially important.

The connection is particularly relevant when chronic venous insufficiency is also present. Persistently elevated venous pressure can increase fluid filtration and overwhelm lymphatic transport. This overlap is known as phlebolymphedema. A 2022 consensus from three vascular medical societies describes how venous dysfunction can overload and eventually damage the lymphatic system. Read the expert consensus on lymphedema.

The potential benefit follows from that physiology: addressing excess filtration caused by venous dysfunction could reduce the fluid load placed on compromised lymphatic vessels. This is a rationale for considering venous support when both problems coexist, and it makes the venous research on diosmin-containing MPFF relevant to the wider conversation about lymphedema.

Research that measured lymphatic transport

Researchers have also studied MPFF directly in people with lymphedema. A 1997 randomized, double-blind, placebo-controlled trial enrolled 104 women with arm lymphedema following breast cancer treatment. Participants received either 1,000 mg of MPFF daily or placebo for six months.

In a subgroup of 24 women with more severe lymphedema, MPFF significantly improved the speed of lymphatic tracer movement on imaging compared with placebo. The overall trial did not show a treatment advantage, and arm-volume reduction was not statistically significant. The subgroup finding provides an exploratory signal that MPFF may influence lymphatic transport. Read the lymphedema trial.

For people living with lymphedema, the practical takeaway is to consider the full fluid-balance picture, including any venous contribution to swelling. Compression, movement, skin care, and specialist-directed lymphatic therapy remain central to care. A treating clinician can help assess whether a supplement has a place in an individual plan. Read the National Cancer Institute overview of lymphedema care.

Why micronized diosmin matters

An ingredient’s physical form can influence how the body absorbs it. Micronization is a process that reduces particle size. For diosmin, this detail has been examined directly in humans.

In a double-blind crossover study, 12 healthy men received single doses of micronized and nonmicronized 500 mg tablet preparations on separate occasions. Researchers used a traceable form of diosmin to compare absorption. The urinary recovery measure used to estimate absorption averaged approximately 58% with the micronized preparation and 33% with the nonmicronized preparation, a statistically significant difference. Read the human micronization study.

The practical lesson is that the ingredient name and milligram amount are only part of a formulation decision. Particle size can matter as well. This study provides a specific reason for choosing micronized diosmin, which is the form used in Lympha.

How this research shaped Lympha

Each 4 mL daily serving of Lympha contains:

• Micronized diosmin: 450 mg
• Hesperidin: 50 mg

Together, they provide 500 mg in a 9:1 ratio. This reflects the diosmin-dominant balance associated with the classic MPFF research and gives the formula a clear connection to an established clinical approach.

Daily amount is part of that context. Both the 2023 swelling review and the lymphedema trial discussed above evaluated 1,000 mg of MPFF daily; Lympha supplies 500 mg of diosmin and hesperidin within its five-active formula. We disclose both amounts so the relationship between the research and the product is straightforward to understand.

The pair sits alongside grape seed extract, gotu kola, and butcher’s broom. We selected these ingredients to address connected aspects of circulation and tissue-fluid balance. Diosmin and hesperidin provide the formula’s main connection to the extensive venous-health literature; the other ingredients bring additional research on small-vessel function and fluid accumulation.

A note on the research: Published results apply to the preparations, doses, and populations studied. They inform our ingredient choices; Lympha’s finished formula has not yet been evaluated in a clinical trial.

A clear reason for the pairing

Diosmin and hesperidin earned their place in Lympha through a clinical record that speaks directly to venous health, leg comfort, and swelling. The human research on micronization adds another concrete reason for the form we chose.

We built Lympha around the physiology of fluid balance, with a specific reason for every ingredient. Diosmin and hesperidin show what that means in practice: a disclosed pair, a defined form, and human research you can read for yourself.

Explore the research behind Lympha.

This article provides general education and does not replace medical advice. Consult a healthcare professional before starting a supplement if you take medication, have a medical condition, or are pregnant or nursing. Persistent or unexplained swelling deserves medical assessment. Lympha is not intended to diagnose, treat, cure, or prevent any disease.